Hepion Pharmaceuticals raises $400K in private placement at $0.05 a share
What's the deal? Hepion PharmaceuticalsDealroom has a profile for this one. Try Dealroom → (OTC: HEPA) has raised roughly $400,000 through a private placement, selling 8,000,000 shares of common stock at $0.05 each to accredited investors. The clinical-stage biopharmaceutical company also issued warrants to purchase an additional 8,000,000 shares.
The terms: The warrants carry an exercise price of $0.06 per share and a five-year term. The securities were issued under an agreement dated August 25, 2026, in a transaction exempt from registration under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D.
What's the endgame? The proceeds give Hepion additional working capital and extend its financial runway as it develops its pipeline.
What could go wrong? The raise underscores the company's continued reliance on outside funding — a common trait among clinical-stage biopharma firms that often burn cash for years before generating revenue.
The signal: At $400,000, the round sits near the bottom of the funding landscape, in roughly the 11th percentile by size. For a small-cap developer, such modest, exempt placements are a routine way to keep the lights on between larger milestones.
Read more: minichart.com.sg
Image credit: foteih
